Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9829 in CD123-positive hematological malignancies
ChiCTR2500104541Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AZD9829 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence, severity, and relationship to AZD9829 of adverse events (AEs) and serious adverse events (SAEs) and 4 more. Started Jun 2025; status: recruiting.
02
Drugs
AZD9829
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2500104541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104541.